Simpler CAR-T therapy tested for tough blood cancers
NCT ID NCT07383233
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a new CAR-T cell therapy that is made inside the body, avoiding the complex and costly lab process. It targets two proteins (CD19 and BAFF-R) on cancer cells in people with relapsed or hard-to-treat B-cell leukemia or lymphoma. The main goals are to check safety and see if the cancer shrinks or disappears.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD19/BAFF-R in vivo CAR-T cells
- What this could lead to
- If successful, this could lead to a simpler, cheaper CAR-T therapy that is easier for patients to access, offering a new option for hard-to-treat blood cancers.
- What could go wrong
- This is a very early Phase 1 trial with only 18 participants, so safety and effectiveness are not yet proven. The therapy may cause serious immune reactions or fail to control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a targeted pill boost Chemotherapy's punch against lymphoma?